Literature DB >> 33259598

Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy.

Timothy J Voorhees1, Nilanjan Ghosh2, Natalie Grover1, Jared Block2, Catherine Cheng1, Kaitlin Morrison1, Anastasia Ivanova1, Gianpietro Dotti1, Jonathan Serody1, Barbara Savoldo1, Anne W Beaven1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33259598      PMCID： PMC7724914          DOI： 10.1182/bloodadvances.2020003218

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  14 in total

1.  How I treat enteropathy-associated T-cell lymphoma.

Authors:  Antonio Di Sabatino; Federico Biagi; Paolo G Gobbi; Gino R Corazza
Journal:  Blood       Date:  2012-01-23       Impact factor: 22.113

2.  Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.

Authors:  Carlos A Ramos; Brandon Ballard; Huimin Zhang; Olga Dakhova; Adrian P Gee; Zhuyong Mei; Mrinalini Bilgi; Meng-Fen Wu; Hao Liu; Bambi Grilley; Catherine M Bollard; Bill H Chang; Cliona M Rooney; Malcolm K Brenner; Helen E Heslop; Gianpietro Dotti; Barbara Savoldo
Journal:  J Clin Invest       Date:  2017-08-14       Impact factor: 14.808

3.  Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.

Authors:  Céline Bossard; Maria Pamela Dobay; Marie Parrens; Laurence Lamant; Edoardo Missiaglia; Corinne Haioun; Antoine Martin; Bettina Fabiani; Richard Delarue; Olivier Tournilhac; Mauro Delorenzi; Philippe Gaulard; Laurence de Leval
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

4.  Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial.

Authors:  Chun-Meng Wang; Zhi-Qiang Wu; Yao Wang; Ye-Lei Guo; Han-Ren Dai; Xiao-Hui Wang; Xiang Li; Ya-Jing Zhang; Wen-Ying Zhang; Mei-Xia Chen; Yan Zhang; Kai-Chao Feng; Yang Liu; Su-Xia Li; Qing-Ming Yang; Wei-Dong Han
Journal:  Clin Cancer Res       Date:  2016-08-31       Impact factor: 12.531

5.  CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.

Authors:  Diogo Gomes-Silva; Madhuwanti Srinivasan; Sandhya Sharma; Ciaran M Lee; Dimitrios L Wagner; Timothy H Davis; Rayne H Rouce; Gang Bao; Malcolm K Brenner; Maksim Mamonkin
Journal:  Blood       Date:  2017-05-24       Impact factor: 22.113

6.  Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma.

Authors:  Waleed F Khalaf; Meghan E Caldwell; Nishitha Reddy
Journal:  J Natl Compr Canc Netw       Date:  2013-02-01       Impact factor: 11.908

7.  Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation.

Authors:  Michal Sieniawski; Nithia Angamuthu; Kathryn Boyd; Richard Chasty; John Davies; Peter Forsyth; Fergus Jack; Simon Lyons; Philip Mounter; Paul Revell; Stephen J Proctor; Anne L Lennard
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

8.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

9.  Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT.

Authors:  Esa Jantunen; Ariane Boumendil; Herve Finel; Jian-Jian Luan; Peter Johnson; Alessandro Rambaldi; Andrew Haynes; Michel A Duchosal; Wolfgang Bethge; Pierre Biron; Kristina Carlson; Charles Craddock; Claudius Rudin; Jurgen Finke; Gilles Salles; Frank Kroschinsky; Anna Sureda; Peter Dreger
Journal:  Blood       Date:  2013-01-29       Impact factor: 22.113

10.  Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.

Authors:  Francesco d'Amore; Thomas Relander; Grete F Lauritzsen; Esa Jantunen; Hans Hagberg; Harald Anderson; Harald Holte; Anders Österborg; Mats Merup; Peter Brown; Outi Kuittinen; Martin Erlanson; Bjørn Østenstad; Unn-Merete Fagerli; Ole V Gadeberg; Christer Sundström; Jan Delabie; Elisabeth Ralfkiaer; Martine Vornanen; Helle E Toldbod
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  3 in total

Review 1.  Beyond CD19 CAR-T cells in lymphoma.

Authors:  Wingchi K Leung; Adanma Ayanambakkam; Helen E Heslop; LaQuisa C Hill
Journal:  Curr Opin Immunol       Date:  2021-11-17       Impact factor: 7.486

Review 2.  Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.

Authors:  Kamila Polgárová; Pavel Otáhal; Cyril Šálek; Robert Pytlík
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

Review 3.  Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials.

Authors:  Maria Ormhøj; Hinrich Abken; Sine R Hadrup
Journal:  Cancer Immunol Immunother       Date:  2022-02-23       Impact factor: 6.630
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.